Stockholm ECS Congress 2010     
EBAC  
  
This programme is accredited by the European Board for Accreditaion in Cardiology (EBAC) for 1 hour external CME credit. Each participant should claim only those hours of credit that have actually been spent in the education activity.

EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
    
Organised by Sahlgrenska Academy, University of Gothenburgh, Sweden

Course Director:
Professor Karl Swedberg Sahlgrenska Academy, University of Gothenburg
  

EBAC ACCREDITED EDUCATIONAL PROGRAMME HELD DURING THE ESC CONGRESS 2010

Chairpersons´ Welcome

Managing Patients with Acute Coronary Syndromes: Current Challenges and Emerging Solutions

Dear esteemed colleagues,

It is our pleasure to invite you to an EBAC Accredited Educational Programme entitled "Managing patients with acute coronary syndromes: current challenges and emerging solutions," presented at the ESC Congress 2010. Our aim in this programme is to provide you with a clear understanding of the significant challenges that remain in the treatment of acute coronary syndromes—with particular focus on the emergency room setting, the cath lab, and patients undergoing coronary artery bypass grafting (CABG)—along with up-to-date guidance on novel approaches for addressing these.

Oral antiplatelet therapy with the P2Y12 receptor inhibitor clopidogrel continues to be a cornerstone of antithrombotic treatment in patients with acute coronary syndromes. However, therapy with clopidogrel has several limitations, including variable interindividual platelet effects, low inhibition of platelet aggregation (IPA), and irreversible inhibition of the P2Y12 receptor.

In this programme, we will provide a brief overview of these limitations, followed by a more in-depth look at the variability in IPA associated with antiplatelet therapy. This variability in treatment response, along with other limitations of clopidogrel treatment, may significantly affect clinical outcome in the emergency room and cath lab, such as increased incidence of stent thrombosis in patients who are poor responders to clopidogrel. In addition, irreversible inhibition of the P2Y12 receptor may complicate management of patients who require CABG or other invasive procedures and therefore become exposed to an increased risk of bleeding. These issues and others will be explored during the course of the programme, and we will conclude with a look forward at emerging therapeutic approaches that may help us overcome some of the limitations of clopidogrel therapy.

We believe this will be a stimulating and rewarding programme; we look forward to welcoming you to Stockholm! 

  
Lars Wallentin
Paul Gurbel
 Lars Wallentin  Paul Gurbel
 
Supported by an unrestricted educational grant from AstraZeneca

In compliance with EBAC/EACCME guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. 		     AstraZeneca      A-PlusScience